CA2947274C — Ophthalmic compositions and methods for treating eyes
Assigned to Hampton Technologies · Expires 2019-03-19 · 7y expired
What this patent protects
Ophthalmic solutions are provided for use as tear substitutes and contact lens solutions. These solutions contain a cationic polymeric surfactant that has an affinity for the surface of the eye or a contact lens. Also disclosed are ophthalmic solutions containing a combination of…
USPTO Abstract
Ophthalmic solutions are provided for use as tear substitutes and contact lens solutions. These solutions contain a cationic polymeric surfactant that has an affinity for the surface of the eye or a contact lens. Also disclosed are ophthalmic solutions containing a combination of the cationic polymeric surfactant and a water soluble anionic polymer which forms a complex in aqueous solution. The complex has an affinity for the surface of the eye or contact lens. In this manner, the present solutions provide improved duration of comfort to the user. The present compositions are also useful as carriers for ophthalmic drugs.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.